The treatment of desmoid tumors: A stepwise clinical approach

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Bonvalot, S ^a   Desai, A ^a   Coppola, S ^a   Le pechoux C ^a   Terrier, P ^a   Domont J ^a   Le cesne, A ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Desmoid; Fibromatosis

Indexed keywords

ANTHRACYCLINE; ANTIESTROGEN; ANTIINFLAMMATORY AGENT; DACARBAZINE; DOXORUBICIN; ESTROGEN RECEPTOR BETA; IMATINIB; INDOMETACIN; MELOXICAM; METHOTREXATE; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SULINDAC; TAMOXIFEN; TEMOZOLOMIDE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ABDOMINAL FIBROMATOSIS; ARTICLE; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; DESMOID TUMOR; DIFFERENTIAL DIAGNOSIS; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; LIMB PERFUSION; MORBIDITY; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME;

ADENOMATOUS POLYPOSIS COLI PROTEIN; BIOPSY; COMBINED MODALITY THERAPY; FIBROMATOSIS, AGGRESSIVE; GERM-LINE MUTATION; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES;

EID: 84866756950     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds298     Document Type: Article

References (47)

1. Cheon SS, Cheah AY, Turley S et al. Beta-catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci USA 2002; 99(10): 6973-6978.
2. Alman BA, Li C, Pajerski ME et al. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997; 151(2): 329-334.
3. Phillips SR, A'Hern R, Thomas JM. Aggressive fibromatosis of the abdominal wall, limbs and limb girdles. Br J Surg 2004; 91(12): 1624-1629.
4. Reitamo JJ, Hayry P, Nykyri E et al. The desmoid tumor. I. Incidence, sex-, ageand anatomical distribution in the Finnish population. Am J Clin Pathol 1982; 77(6): 665-673.
5. Meazza C, Bisogno G, Gronchi A et al. Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer 2010; 116(1): 233-240.
6. Fiore M, Rimareix F, Mariani L et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009; 16(9): 2587-2593.
7. Bertagnolli MM, Morgan JA, Fletcher CD et al. Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer 2008; 44(16): 2404-2410.
8. de Bree E, Keus R, Melissas J et al. Desmoid tumors: need for an individualized approach. Expert Rev Anticancer Ther 2009; 9(4): 525-535.
9. Johner A, Tiwari P, Zetler P et al. Abdominal wall desmoid tumors associated with pregnancy: current concepts. Expert Rev Anticancer Ther 2009; 9(11): 1675-1682.
10. Castellazzi G, Vanel D, Le Cesne A et al. Can the MRI signal of aggressive fibromatosis be used to predict its behavior? Eur J Radiol 2009; 69(2): 222-229.
11. Casali PG, Jost L, Sleijfer S et al. ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and followup. Ann Oncol 2009; 20(Suppl 4): 132-136.
12. Dômont J, Salas S, Lacroix L et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer 2010; 102(6): 1032-1036.
13. Francis WP, Zippel D, Mack LA et al. Desmoids: a revelation in biology and treatment. Ann Surg Oncol 2009; 16(6): 1650-1654.
14. Ballo MT, Zagars GK, Pollack A et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999; 17(1): 158-167.
15. Rock MG, Pritchard DJ, Reiman HM et al. Extra-abdominal desmoid tumors. J Bone Joint Surg Am 1984; 66(9): 1369-1374.
16. Stojadinovic A, Leung DH, Hoos A et al. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 2002; 235(3): 424-434.
17. Spear MA, Jennings LC, Mankin HJ et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys 1998; 40(3): 637-645.
18. Bonvalot S, Eldweny H, Haddad V et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008; 34(4): 462-468.
19. Merchant NB, Lewis JJ, Woodruff JM et al. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 1999; 86(10): 2045-2052.
20. Gronchi A, Casali PG, Mariani L et al. Quality of surgery and outcome in extraabdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 2003; 21(7): 1390-1397.
21. Cheon SS, Nadesan P, Poon R et al. Growth factors regulate beta-cateninmediated TCF-dependent transcriptional activation in fibroblasts during the proliferative phase of wound healing. Exp Cell Res 2004; 293(2): 267-274.
22. Baumert BG, Spahr MO, Von Hochstetter A et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiat Oncol 2007; 2: 12.
23. Lewis JJ, Boland PJ, Leung DH et al. The enigma of desmoid tumors. Ann Surg 1999; 229(6): 866-872.
24. Salas S, Dufresne A, Bui B et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 2011; 29(26): 3553-3558.
25. Stoeckle E, Coindre JM, Longy M et al. A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. Eur J Surg Oncol 2009; 35(2): 129-134.
26. Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG et al. Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Br J Cancer 2011; 104(1): 37-42.
27. Ray ME, Lawrence TS. Radiation therapy for aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24(22): 3714-3715.
28. Nuyttens JJ, Rust PF, Thomas CR, Jr et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer 2000; 88(7): 1517-1523.
29. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys 2008; 71(2): 441-447.
30. Lev D, Kotilingam D, Wei C et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007; 25(13): 1785-1791.
31. de Camargo VP, Keohan ML, D'Adamo DR et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010; 116 (9): 2258-2265.
32. Hansmann A, Adolph C, Vogel T et al. High-dose tamoxifen and sulindac as firstline treatment for desmoid tumors. Cancer 2004; 100(3): 612-620.
33. Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer 2006; 106(1): 208-213.
34. Signoroni S, Frattini M, Negri T et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res 2007; 13(17): 5034-5040.
35. Poon R, Smits R, Li C et al. Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 2001; 20(4): 451-460.
36. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer 1993; 72(11): 3244-3247.
37. Gega M, Yanagi H, Yoshikawa R et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006; 24(1): 102-105.
38. Heinrich MC, McArthur GA, Demetri GD et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24(7): 1195-1203.
39. Chugh R, Wathen JK, Patel SR et al. Sarcoma Alliance for Research through Collaboration (SARC). Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 2010; 16(19): 4884-4891.
40. Penel N, Le Cesne A, Bui BN et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 2011; 22(2): 452-457.
41. Dufresne A, Bertucci F, Penel N et al. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. Br J Cancer 2010; 103(4): 482-485.
42. Gounder MM, Antonescu C, Hameed MR et al. Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF). J Clin Oncol 2010; 28: 15s (suppl; abstr 10013).
43. Bonvalot S, Rimareix F, Causeret S et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol 2009; 16(12): 3350-3357.
44. Kujak JL, Liu PT, Johnson GB et al. Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors. Skeletal Radiol 2010; 39: 175-182.
45. Lazar AJ, Tuvin D, Hajibashi S et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008; 173(5): 1518-1527.
46. Colombo C, Miceli R, Bolshakov S et al. CTNNB1 45F mutation is a potential molecular prognosticator of increased primary desmoid recurrence: an independent cohort validation study. In Combined Meeting of the Connective Tissue Oncology Society and the Musculoskeletal Tumor Society, October 26-29, 2011, Chicago, IL 2011.
47. Salas S, Chibon F, Noguchi T et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer 2010; 49(6): 560-568.